Abstract
Purpose
PD-1 Immunotherapy is integral in treating multiple cancers, but has been associated with neurological adverse events (nAEs). Our study was aimed at identifying the clinical spectrum of nAEs associated with pembrolizumab and nivolumab.
Methods
We performed an IRB approved single-center retrospective cohort study on patients receiving either pembrolizumab or nivolumab. Patients that developed nAEs within 12 months of treatment were identified. Descriptive statistics were conducted, and differences between groups were analyzed by the Chi-square or t test method.
Results
In total, 649 patients were identified. Seventeen patients (2.6%) developed nAEs. Eight of those were on pembrolizumab and nine were on nivolumab. Average age was 62.1 years. Ten were males and 7 were females. Most patients had melanoma (6, 35.3%). Patients who developed nAEs more frequently had intracranial lesions at initiation of anti PD-1 therapy compared to those who did not develop nAEs (76.5% vs 27.8%; p-value < 0.001). Fifteen patients (88.2%) permanently stopped PD-1 therapy. In 8 patients, treatment termination resolved symptoms attributed to immune checkpoint blockade. The majority of patients developed grade 3 or 4 nAEs (10 patients, 58.8%), and required hospitalization (11 patients, 64.7%). Eight patients died for nAEs referable causes.
Conclusion
Pembrolizumab and nivolumab are associated with the development of nAEs associated with increased risk of permanent discontinuation of treatment, hospitalization, and death. Melanoma patients might be at a particularly high risk of such side effects. Future studies are still required to better assess which patients benefit most from such therapies, while minimizing the risk of complications.
Similar content being viewed by others
References
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34
Weber JS, D'Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639
Rizvi NA, Mazieres J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257–265
Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
Cloughesy TF, Mochizuki AY, Orpilla JR et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477–486. https://doi.org/10.1038/s41591-018-0337-7
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25(3):470–476
Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216–1222
Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225
Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239
Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https://doi.org/10.3389/fonc.2018.00086
Doron H, Amer M, Ershaid N et al (2019) Inflammatory activation of astrocytes facilitates melanoma brain tropism via the CXCL10-CXCR3 signaling axis. Cell Rep 28:1785–1798.e6. https://doi.org/10.1016/j.celrep.2019.07.033
Polat P, Donofrio PD (2016) Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 54(3):507
Lau KH, Kumar A, Yang IH, Nowak RJ (2016) Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54(1):157–161
Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ, Zappia M (2016) Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 54(3):507–509
Aya F, Ruiz-Esquide V, Viladot M et al (2017) Vasculitic neuropathy induced by pembrolizumab. Ann Oncol 28(2):433–434
de Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375(3):296–297
Tanaka R, Maruyama H, Tomidokoro Y et al (2016) Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol 46(9):875–878
Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW (2014) Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 344(1–2):229–231
Salam S, Lavin T, Turan A (2016) Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-215012
Roberts P, Fishman GA, Joshi K, Jampol LM (2016) Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol 134(10):1184–1188
Garcia CA, El-Ali A, Rath TJ et al (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. https://doi.org/10.1186/s40425-018-0393-z
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16:589–593. https://doi.org/10.1093/neuonc/nou001
Di Giacomo AM, Valente M, Cerase A et al (2019) Immunotherapy of brain metastases: breaking a “dogma”. J Exp Clin Cancer Res 38:419. https://doi.org/10.1186/s13046-019-1426-2
University of Pittsburgh CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02058953. Accessed 25 Mar 2020
Acknowledgements
We would like to thank all patients who participated in our study.
Funding
No financial support or fund was granted for the making of this project.
Author information
Authors and Affiliations
Contributions
Experimental Design and Implementation: SS, JAJ, MJ, RK, VV, EE, RT and JM. Data Analysis and Interpretation: SS, JAJ, MJ, RK, VV, EE, RT and JM. Writing of the Manuscript: SS, JAJ, MJ, RK, VV, EE, RT and JM. Approval of Final Version: all co-authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest in the making of this project.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shi, S., Jaoube, J.A., Kanwar, R. et al. Neurological adverse effects due to programmed death 1 (PD-1) inhibitors. J Neurooncol 148, 291–297 (2020). https://doi.org/10.1007/s11060-020-03514-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-020-03514-8